Integration of PARP-inhibitors in ovarian cancer therapy
Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unp...
Ausführliche Beschreibung
Autor*in: |
Antonella Pietragalla [verfasserIn] Francesca Ciccarone [verfasserIn] Camilla Nero [verfasserIn] Giovanni Scambia [verfasserIn] Domenica Lorusso [verfasserIn] Gennaro Daniele [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2020 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Exploration of Targeted Anti-tumor Therapy - Open Exploration Publishing Inc., 2021, 1(2020), 3, Seite 171-182 |
---|---|
Übergeordnetes Werk: |
volume:1 ; year:2020 ; number:3 ; pages:171-182 |
Links: |
---|
DOI / URN: |
10.37349/etat.2020.00011 |
---|
Katalog-ID: |
DOAJ061689122 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ061689122 | ||
003 | DE-627 | ||
005 | 20230309013236.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230228s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.37349/etat.2020.00011 |2 doi | |
035 | |a (DE-627)DOAJ061689122 | ||
035 | |a (DE-599)DOAJ79312cdaaf644f7183b9e74b8902906e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC31-1245 | |
100 | 0 | |a Antonella Pietragalla |e verfasserin |4 aut | |
245 | 1 | 0 | |a Integration of PARP-inhibitors in ovarian cancer therapy |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients. | ||
650 | 4 | |a parp-inhibitors | |
650 | 4 | |a ovarian cancer | |
650 | 4 | |a brca1 and 2 | |
650 | 4 | |a homologous recombination deficiency | |
650 | 4 | |a dna repair | |
653 | 0 | |a Internal medicine | |
700 | 0 | |a Francesca Ciccarone |e verfasserin |4 aut | |
700 | 0 | |a Camilla Nero |e verfasserin |4 aut | |
700 | 0 | |a Giovanni Scambia |e verfasserin |4 aut | |
700 | 0 | |a Domenica Lorusso |e verfasserin |4 aut | |
700 | 0 | |a Gennaro Daniele |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Exploration of Targeted Anti-tumor Therapy |d Open Exploration Publishing Inc., 2021 |g 1(2020), 3, Seite 171-182 |w (DE-627)174398264X |x 26923114 |7 nnns |
773 | 1 | 8 | |g volume:1 |g year:2020 |g number:3 |g pages:171-182 |
856 | 4 | 0 | |u https://doi.org/10.37349/etat.2020.00011 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/79312cdaaf644f7183b9e74b8902906e |z kostenfrei |
856 | 4 | 0 | |u https://www.explorationpub.com/Journals/etat/Article/100211 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2692-3114 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 1 |j 2020 |e 3 |h 171-182 |
author_variant |
a p ap f c fc c n cn g s gs d l dl g d gd |
---|---|
matchkey_str |
article:26923114:2020----::nertooprihbtrioain |
hierarchy_sort_str |
2020 |
callnumber-subject-code |
RC |
publishDate |
2020 |
allfields |
10.37349/etat.2020.00011 doi (DE-627)DOAJ061689122 (DE-599)DOAJ79312cdaaf644f7183b9e74b8902906e DE-627 ger DE-627 rakwb eng RC31-1245 Antonella Pietragalla verfasserin aut Integration of PARP-inhibitors in ovarian cancer therapy 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients. parp-inhibitors ovarian cancer brca1 and 2 homologous recombination deficiency dna repair Internal medicine Francesca Ciccarone verfasserin aut Camilla Nero verfasserin aut Giovanni Scambia verfasserin aut Domenica Lorusso verfasserin aut Gennaro Daniele verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 3, Seite 171-182 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:3 pages:171-182 https://doi.org/10.37349/etat.2020.00011 kostenfrei https://doaj.org/article/79312cdaaf644f7183b9e74b8902906e kostenfrei https://www.explorationpub.com/Journals/etat/Article/100211 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 3 171-182 |
spelling |
10.37349/etat.2020.00011 doi (DE-627)DOAJ061689122 (DE-599)DOAJ79312cdaaf644f7183b9e74b8902906e DE-627 ger DE-627 rakwb eng RC31-1245 Antonella Pietragalla verfasserin aut Integration of PARP-inhibitors in ovarian cancer therapy 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients. parp-inhibitors ovarian cancer brca1 and 2 homologous recombination deficiency dna repair Internal medicine Francesca Ciccarone verfasserin aut Camilla Nero verfasserin aut Giovanni Scambia verfasserin aut Domenica Lorusso verfasserin aut Gennaro Daniele verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 3, Seite 171-182 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:3 pages:171-182 https://doi.org/10.37349/etat.2020.00011 kostenfrei https://doaj.org/article/79312cdaaf644f7183b9e74b8902906e kostenfrei https://www.explorationpub.com/Journals/etat/Article/100211 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 3 171-182 |
allfields_unstemmed |
10.37349/etat.2020.00011 doi (DE-627)DOAJ061689122 (DE-599)DOAJ79312cdaaf644f7183b9e74b8902906e DE-627 ger DE-627 rakwb eng RC31-1245 Antonella Pietragalla verfasserin aut Integration of PARP-inhibitors in ovarian cancer therapy 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients. parp-inhibitors ovarian cancer brca1 and 2 homologous recombination deficiency dna repair Internal medicine Francesca Ciccarone verfasserin aut Camilla Nero verfasserin aut Giovanni Scambia verfasserin aut Domenica Lorusso verfasserin aut Gennaro Daniele verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 3, Seite 171-182 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:3 pages:171-182 https://doi.org/10.37349/etat.2020.00011 kostenfrei https://doaj.org/article/79312cdaaf644f7183b9e74b8902906e kostenfrei https://www.explorationpub.com/Journals/etat/Article/100211 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 3 171-182 |
allfieldsGer |
10.37349/etat.2020.00011 doi (DE-627)DOAJ061689122 (DE-599)DOAJ79312cdaaf644f7183b9e74b8902906e DE-627 ger DE-627 rakwb eng RC31-1245 Antonella Pietragalla verfasserin aut Integration of PARP-inhibitors in ovarian cancer therapy 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients. parp-inhibitors ovarian cancer brca1 and 2 homologous recombination deficiency dna repair Internal medicine Francesca Ciccarone verfasserin aut Camilla Nero verfasserin aut Giovanni Scambia verfasserin aut Domenica Lorusso verfasserin aut Gennaro Daniele verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 3, Seite 171-182 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:3 pages:171-182 https://doi.org/10.37349/etat.2020.00011 kostenfrei https://doaj.org/article/79312cdaaf644f7183b9e74b8902906e kostenfrei https://www.explorationpub.com/Journals/etat/Article/100211 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 3 171-182 |
allfieldsSound |
10.37349/etat.2020.00011 doi (DE-627)DOAJ061689122 (DE-599)DOAJ79312cdaaf644f7183b9e74b8902906e DE-627 ger DE-627 rakwb eng RC31-1245 Antonella Pietragalla verfasserin aut Integration of PARP-inhibitors in ovarian cancer therapy 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients. parp-inhibitors ovarian cancer brca1 and 2 homologous recombination deficiency dna repair Internal medicine Francesca Ciccarone verfasserin aut Camilla Nero verfasserin aut Giovanni Scambia verfasserin aut Domenica Lorusso verfasserin aut Gennaro Daniele verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 3, Seite 171-182 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:3 pages:171-182 https://doi.org/10.37349/etat.2020.00011 kostenfrei https://doaj.org/article/79312cdaaf644f7183b9e74b8902906e kostenfrei https://www.explorationpub.com/Journals/etat/Article/100211 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 3 171-182 |
language |
English |
source |
In Exploration of Targeted Anti-tumor Therapy 1(2020), 3, Seite 171-182 volume:1 year:2020 number:3 pages:171-182 |
sourceStr |
In Exploration of Targeted Anti-tumor Therapy 1(2020), 3, Seite 171-182 volume:1 year:2020 number:3 pages:171-182 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
parp-inhibitors ovarian cancer brca1 and 2 homologous recombination deficiency dna repair Internal medicine |
isfreeaccess_bool |
true |
container_title |
Exploration of Targeted Anti-tumor Therapy |
authorswithroles_txt_mv |
Antonella Pietragalla @@aut@@ Francesca Ciccarone @@aut@@ Camilla Nero @@aut@@ Giovanni Scambia @@aut@@ Domenica Lorusso @@aut@@ Gennaro Daniele @@aut@@ |
publishDateDaySort_date |
2020-01-01T00:00:00Z |
hierarchy_top_id |
174398264X |
id |
DOAJ061689122 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ061689122</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309013236.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.37349/etat.2020.00011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ061689122</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ79312cdaaf644f7183b9e74b8902906e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC31-1245</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Antonella Pietragalla</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Integration of PARP-inhibitors in ovarian cancer therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">parp-inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ovarian cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">brca1 and 2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">homologous recombination deficiency</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dna repair</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesca Ciccarone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Camilla Nero</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giovanni Scambia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Domenica Lorusso</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gennaro Daniele</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Exploration of Targeted Anti-tumor Therapy</subfield><subfield code="d">Open Exploration Publishing Inc., 2021</subfield><subfield code="g">1(2020), 3, Seite 171-182</subfield><subfield code="w">(DE-627)174398264X</subfield><subfield code="x">26923114</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:171-182</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.37349/etat.2020.00011</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/79312cdaaf644f7183b9e74b8902906e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.explorationpub.com/Journals/etat/Article/100211</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2692-3114</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2020</subfield><subfield code="e">3</subfield><subfield code="h">171-182</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Antonella Pietragalla |
spellingShingle |
Antonella Pietragalla misc RC31-1245 misc parp-inhibitors misc ovarian cancer misc brca1 and 2 misc homologous recombination deficiency misc dna repair misc Internal medicine Integration of PARP-inhibitors in ovarian cancer therapy |
authorStr |
Antonella Pietragalla |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)174398264X |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC31-1245 |
illustrated |
Not Illustrated |
issn |
26923114 |
topic_title |
RC31-1245 Integration of PARP-inhibitors in ovarian cancer therapy parp-inhibitors ovarian cancer brca1 and 2 homologous recombination deficiency dna repair |
topic |
misc RC31-1245 misc parp-inhibitors misc ovarian cancer misc brca1 and 2 misc homologous recombination deficiency misc dna repair misc Internal medicine |
topic_unstemmed |
misc RC31-1245 misc parp-inhibitors misc ovarian cancer misc brca1 and 2 misc homologous recombination deficiency misc dna repair misc Internal medicine |
topic_browse |
misc RC31-1245 misc parp-inhibitors misc ovarian cancer misc brca1 and 2 misc homologous recombination deficiency misc dna repair misc Internal medicine |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Exploration of Targeted Anti-tumor Therapy |
hierarchy_parent_id |
174398264X |
hierarchy_top_title |
Exploration of Targeted Anti-tumor Therapy |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)174398264X |
title |
Integration of PARP-inhibitors in ovarian cancer therapy |
ctrlnum |
(DE-627)DOAJ061689122 (DE-599)DOAJ79312cdaaf644f7183b9e74b8902906e |
title_full |
Integration of PARP-inhibitors in ovarian cancer therapy |
author_sort |
Antonella Pietragalla |
journal |
Exploration of Targeted Anti-tumor Therapy |
journalStr |
Exploration of Targeted Anti-tumor Therapy |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2020 |
contenttype_str_mv |
txt |
container_start_page |
171 |
author_browse |
Antonella Pietragalla Francesca Ciccarone Camilla Nero Giovanni Scambia Domenica Lorusso Gennaro Daniele |
container_volume |
1 |
class |
RC31-1245 |
format_se |
Elektronische Aufsätze |
author-letter |
Antonella Pietragalla |
doi_str_mv |
10.37349/etat.2020.00011 |
author2-role |
verfasserin |
title_sort |
integration of parp-inhibitors in ovarian cancer therapy |
callnumber |
RC31-1245 |
title_auth |
Integration of PARP-inhibitors in ovarian cancer therapy |
abstract |
Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients. |
abstractGer |
Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients. |
abstract_unstemmed |
Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
3 |
title_short |
Integration of PARP-inhibitors in ovarian cancer therapy |
url |
https://doi.org/10.37349/etat.2020.00011 https://doaj.org/article/79312cdaaf644f7183b9e74b8902906e https://www.explorationpub.com/Journals/etat/Article/100211 https://doaj.org/toc/2692-3114 |
remote_bool |
true |
author2 |
Francesca Ciccarone Camilla Nero Giovanni Scambia Domenica Lorusso Gennaro Daniele |
author2Str |
Francesca Ciccarone Camilla Nero Giovanni Scambia Domenica Lorusso Gennaro Daniele |
ppnlink |
174398264X |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.37349/etat.2020.00011 |
callnumber-a |
RC31-1245 |
up_date |
2024-07-03T22:10:38.872Z |
_version_ |
1803597527251943424 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ061689122</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309013236.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.37349/etat.2020.00011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ061689122</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ79312cdaaf644f7183b9e74b8902906e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC31-1245</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Antonella Pietragalla</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Integration of PARP-inhibitors in ovarian cancer therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">parp-inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ovarian cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">brca1 and 2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">homologous recombination deficiency</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dna repair</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesca Ciccarone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Camilla Nero</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giovanni Scambia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Domenica Lorusso</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gennaro Daniele</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Exploration of Targeted Anti-tumor Therapy</subfield><subfield code="d">Open Exploration Publishing Inc., 2021</subfield><subfield code="g">1(2020), 3, Seite 171-182</subfield><subfield code="w">(DE-627)174398264X</subfield><subfield code="x">26923114</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:171-182</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.37349/etat.2020.00011</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/79312cdaaf644f7183b9e74b8902906e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.explorationpub.com/Journals/etat/Article/100211</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2692-3114</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2020</subfield><subfield code="e">3</subfield><subfield code="h">171-182</subfield></datafield></record></collection>
|
score |
7.4020653 |